At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Janice Tsang, MBBS, MRCP(UK), FRCP(Edin), FHKCP, FHKAM (Medicine), from The University of Hong Kong, Hong Kong, explains the clinical relevance of promising molecular targets, including alterations affecting the ESR1 gene and the PI3K signalling pathway, in the development of targeted therapies for patients with metastatic breast cancer.
Precision medicine for metastatic breast cancer
9th March 2016
Oncology
Rate this content's potential impact on patient outcomes
Thank you!
Please share some more information on the rating you have given